Cargando…
Immune‐Related Adverse Events in the Setting of PD‐1/L1 Inhibitor Combination Therapy
In 2018, a multi‐disciplinary workshop was held at the Massachusetts General Hospital to discuss challenges in defining, diagnosing, and treating immune‐related adverse events (irAE), including those that occur in patients administered PD‐1/L1 inhibitor combination therapy. In this commentary, the w...
| Autores principales: | , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley & Sons, Inc.
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7066708/ https://www.ncbi.nlm.nih.gov/pubmed/32162817 http://dx.doi.org/10.1634/theoncologist.2018-0883 |
| _version_ | 1783505294390722560 |
|---|---|
| author | Zubiri, Leyre Allen, Ian M. Taylor, Martin S. Guidon, Amanda C. Chen, Steven T. Schoenfeld, Sara R. Neilan, Tomas G. Sise, Meghan E. Mooradian, Meghan J. Rubin, Krista M. Leaf, Rebecca Karp Parikh, Aparna R. Faje, Alexander Gainor, Justin F. Cohen, Justine V. Fintelmann, Florian J. Kohler, Minna J. Dougan, Michael Reynolds, Kerry L. |
| author_facet | Zubiri, Leyre Allen, Ian M. Taylor, Martin S. Guidon, Amanda C. Chen, Steven T. Schoenfeld, Sara R. Neilan, Tomas G. Sise, Meghan E. Mooradian, Meghan J. Rubin, Krista M. Leaf, Rebecca Karp Parikh, Aparna R. Faje, Alexander Gainor, Justin F. Cohen, Justine V. Fintelmann, Florian J. Kohler, Minna J. Dougan, Michael Reynolds, Kerry L. |
| author_sort | Zubiri, Leyre |
| collection | PubMed |
| description | In 2018, a multi‐disciplinary workshop was held at the Massachusetts General Hospital to discuss challenges in defining, diagnosing, and treating immune‐related adverse events (irAE), including those that occur in patients administered PD‐1/L1 inhibitor combination therapy. In this commentary, the workshop participants present a clinical case that illustrates the complexity of irAE diagnosis and management in a patient receiving PD‐1/L1 combination therapy, summarize the current state of PD‐1/L1 combination therapy, and discuss challenges and opportunities for the evaluation of irAEs as these combinations become more widely used to treat patients with cancer. |
| format | Online Article Text |
| id | pubmed-7066708 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2019 |
| publisher | John Wiley & Sons, Inc. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-70667082020-04-06 Immune‐Related Adverse Events in the Setting of PD‐1/L1 Inhibitor Combination Therapy Zubiri, Leyre Allen, Ian M. Taylor, Martin S. Guidon, Amanda C. Chen, Steven T. Schoenfeld, Sara R. Neilan, Tomas G. Sise, Meghan E. Mooradian, Meghan J. Rubin, Krista M. Leaf, Rebecca Karp Parikh, Aparna R. Faje, Alexander Gainor, Justin F. Cohen, Justine V. Fintelmann, Florian J. Kohler, Minna J. Dougan, Michael Reynolds, Kerry L. Oncologist Commentaries In 2018, a multi‐disciplinary workshop was held at the Massachusetts General Hospital to discuss challenges in defining, diagnosing, and treating immune‐related adverse events (irAE), including those that occur in patients administered PD‐1/L1 inhibitor combination therapy. In this commentary, the workshop participants present a clinical case that illustrates the complexity of irAE diagnosis and management in a patient receiving PD‐1/L1 combination therapy, summarize the current state of PD‐1/L1 combination therapy, and discuss challenges and opportunities for the evaluation of irAEs as these combinations become more widely used to treat patients with cancer. John Wiley & Sons, Inc. 2019-11-21 2020-03 /pmc/articles/PMC7066708/ /pubmed/32162817 http://dx.doi.org/10.1634/theoncologist.2018-0883 Text en © 2019 The Authors. The Oncologist published by Wiley Periodicals, Inc. on behalf of AlphaMed Press. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
| spellingShingle | Commentaries Zubiri, Leyre Allen, Ian M. Taylor, Martin S. Guidon, Amanda C. Chen, Steven T. Schoenfeld, Sara R. Neilan, Tomas G. Sise, Meghan E. Mooradian, Meghan J. Rubin, Krista M. Leaf, Rebecca Karp Parikh, Aparna R. Faje, Alexander Gainor, Justin F. Cohen, Justine V. Fintelmann, Florian J. Kohler, Minna J. Dougan, Michael Reynolds, Kerry L. Immune‐Related Adverse Events in the Setting of PD‐1/L1 Inhibitor Combination Therapy |
| title | Immune‐Related Adverse Events in the Setting of PD‐1/L1 Inhibitor Combination Therapy |
| title_full | Immune‐Related Adverse Events in the Setting of PD‐1/L1 Inhibitor Combination Therapy |
| title_fullStr | Immune‐Related Adverse Events in the Setting of PD‐1/L1 Inhibitor Combination Therapy |
| title_full_unstemmed | Immune‐Related Adverse Events in the Setting of PD‐1/L1 Inhibitor Combination Therapy |
| title_short | Immune‐Related Adverse Events in the Setting of PD‐1/L1 Inhibitor Combination Therapy |
| title_sort | immune‐related adverse events in the setting of pd‐1/l1 inhibitor combination therapy |
| topic | Commentaries |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7066708/ https://www.ncbi.nlm.nih.gov/pubmed/32162817 http://dx.doi.org/10.1634/theoncologist.2018-0883 |
| work_keys_str_mv | AT zubirileyre immunerelatedadverseeventsinthesettingofpd1l1inhibitorcombinationtherapy AT allenianm immunerelatedadverseeventsinthesettingofpd1l1inhibitorcombinationtherapy AT taylormartins immunerelatedadverseeventsinthesettingofpd1l1inhibitorcombinationtherapy AT guidonamandac immunerelatedadverseeventsinthesettingofpd1l1inhibitorcombinationtherapy AT chenstevent immunerelatedadverseeventsinthesettingofpd1l1inhibitorcombinationtherapy AT schoenfeldsarar immunerelatedadverseeventsinthesettingofpd1l1inhibitorcombinationtherapy AT neilantomasg immunerelatedadverseeventsinthesettingofpd1l1inhibitorcombinationtherapy AT sisemeghane immunerelatedadverseeventsinthesettingofpd1l1inhibitorcombinationtherapy AT mooradianmeghanj immunerelatedadverseeventsinthesettingofpd1l1inhibitorcombinationtherapy AT rubinkristam immunerelatedadverseeventsinthesettingofpd1l1inhibitorcombinationtherapy AT leafrebeccakarp immunerelatedadverseeventsinthesettingofpd1l1inhibitorcombinationtherapy AT parikhaparnar immunerelatedadverseeventsinthesettingofpd1l1inhibitorcombinationtherapy AT fajealexander immunerelatedadverseeventsinthesettingofpd1l1inhibitorcombinationtherapy AT gainorjustinf immunerelatedadverseeventsinthesettingofpd1l1inhibitorcombinationtherapy AT cohenjustinev immunerelatedadverseeventsinthesettingofpd1l1inhibitorcombinationtherapy AT fintelmannflorianj immunerelatedadverseeventsinthesettingofpd1l1inhibitorcombinationtherapy AT kohlerminnaj immunerelatedadverseeventsinthesettingofpd1l1inhibitorcombinationtherapy AT douganmichael immunerelatedadverseeventsinthesettingofpd1l1inhibitorcombinationtherapy AT reynoldskerryl immunerelatedadverseeventsinthesettingofpd1l1inhibitorcombinationtherapy |